Dr. Thomas L. Ortel

Murat Arcasoy is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Arcasoy is rated as a Distinguished provider by MediFind in the treatment of Multicentric Castleman Disease (MCD). His top areas of expertise are Essential Thrombocythemia, Polycythemia Vera, Myelofibrosis, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Bone Marrow Aspiration. Dr. Arcasoy is currently accepting new patients.

I study disorders of the bone marrow and bone marrow failure syndromes. I also see some leukemias and lymphomas and other blood malignancies. Duke offers a very personalized, individualized level of care to each patient. Nobody is the same, so we take the whole patient, we listen to them, and we offer our best recommendations for treatment options. We offer some of the latest treatment options that are available, usually in the setting of a clinical trial. If not, we offer the latest advancement in the field. When I was going through medical school, molecular biology was the new field. Everything was being described as a new cancer-causing gene. And to me that was so appealing – we’re going to figure out what causes cancer and new ways to treat it. That’s what really brought me into the hematology oncology world – things were being discovered that were new and exciting and hopefully would lead to new treatment options. Duke offers an extremely high standard of care. Though we’re not always successful and the disease sometimes wins, our goal is to give the patients the best possible care. Dr. Decastro is rated as a Distinguished provider by MediFind in the treatment of Multicentric Castleman Disease (MCD). His top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Aplastic Anemia, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.

I have the privilege of caring for patients with various myeloproliferative neoplasms including, polycythemia vera, essential thrombocytosis, primary myelofibrosis, systemic mastocytosis, and chronic myeloid leukemia. My goal is to provide the best possible care for each individual patient in an era where the number of therapeutic options for patients with myeloproliferative neoplasms is rapidly expanding. As a clinical investigator leading several clinical studies in both early and late stages of development, I strive to offer patients access to investigational agents with novel mechanisms of action via participation in clinical trials. I believe that every patient has a unique diagnosis and personal experience with their cancer. I aim to consider the disease, the patient and individual care goals in partnering with patients to develop and implement personalized treatment plans. Dr. Rein is rated as a Distinguished provider by MediFind in the treatment of Multicentric Castleman Disease (MCD). Her top areas of expertise are Systemic Mastocytosis, Myelofibrosis, Myeloproliferative Neoplasms (MPN), Acute Myeloid Leukemia (AML), and Bone Marrow Aspiration.